Association Between Rotavirus Vaccination and Type 1 Diabetes in Children.


Journal

JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544

Informations de publication

Date de publication:
01 05 2020
Historique:
pubmed: 10 3 2020
medline: 25 3 2021
entrez: 10 3 2020
Statut: ppublish

Résumé

Because rotavirus infection is a hypothesized risk factor for type 1 diabetes, live attenuated rotavirus vaccination could increase or decrease the risk of type 1 diabetes in children. To examine whether there is an association between rotavirus vaccination and incidence of type 1 diabetes in children aged 8 months to 11 years. A retrospective cohort study of 386 937 children born between January 1, 2006, and December 31, 2014, was conducted in 7 US health care organizations of the Vaccine Safety Datalink. Eligible children were followed up until a diagnosis of type 1 diabetes, disenrollment, or December 31, 2017. Rotavirus vaccination for children aged 2 to 8 months. Three exposure groups were created. The first group included children who received all recommended doses of rotavirus vaccine by 8 months of age (fully exposed to rotavirus vaccination). The second group had received some, but not all, recommended rotavirus vaccines (partially exposed to rotavirus vaccination). The third group did not receive any doses of rotavirus vaccines (unexposed to rotavirus vaccination). Incidence of type 1 diabetes among children aged 8 months to 11 years. Type 1 diabetes was identified by International Classification of Diseases codes: 250.x1, 250.x3, or E10.xx in the outpatient setting. Cox proportional hazards regression models were used to analyze time to type 1 diabetes incidence from 8 months to 11 years. Hazard ratios and 95% CIs were calculated. Models were adjusted for sex, race/ethnicity, birth year, mother's age, birth weight, gestational age, number of well-child visits, and Vaccine Safety Datalink site. In a cohort of 386 937 children (51.1% boys and 41.9% non-Hispanic white), 360 169 (93.1%) were fully exposed to rotavirus vaccination, 15 765 (4.1%) were partially exposed to rotavirus vaccination, and 11 003 (2.8%) were unexposed to rotavirus vaccination. Children were followed up a median of 5.4 years (interquartile range, 3.8-7.8 years). The total person-time follow-up in the cohort was 2 253 879 years. There were 464 cases of type 1 diabetes in the cohort, with an incidence rate of 20.6 cases per 100 000 person-years. Compared with children unexposed to rotavirus vaccination, the adjusted hazard ratio was 1.03 (95% CI, 0.62-1.72) for children fully exposed to rotavirus vaccination and 1.50 (95% CI, 0.81-2.77) for children partially exposed to rotavirus vaccination. The findings of this study suggest that rotavirus vaccination does not appear to be associated with type 1 diabetes in children.

Identifiants

pubmed: 32150236
pii: 2762009
doi: 10.1001/jamapediatrics.2019.6324
pmc: PMC7063538
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

455-462

Références

JAMA Pediatr. 2013 Mar 1;167(3):274-81
pubmed: 23338829
Am J Perinatol. 2018 Dec;35(14):1394-1398
pubmed: 29883982
BMC Med. 2017 Nov 8;15(1):199
pubmed: 29115947
J Virol. 2007 Jun;81(12):6446-58
pubmed: 17428851
J Clin Epidemiol. 2006 Oct;59(10):1092-101
pubmed: 16980150
Diabetes. 2000 Aug;49(8):1319-24
pubmed: 10923632
Am J Epidemiol. 1999 Jan 15;149(2):186-94
pubmed: 9921964
Pediatrics. 2015 Feb;135(2):280-9
pubmed: 25601971
PLoS One. 2014 Sep 02;9(9):e106560
pubmed: 25181416
Pharmacoepidemiol Drug Saf. 2018 Oct;27(10):1053-1059
pubmed: 29292555
Diabetes Care. 1999 Jun;22(6):928-32
pubmed: 10372244
Am J Epidemiol. 2007 Sep 1;166(5):495-505
pubmed: 17575306
Pediatrics. 2004 Jul;114(1):187-95
pubmed: 15231927
Pediatrics. 2011 May;127 Suppl 1:S45-53
pubmed: 21502240
Am J Epidemiol. 2014 Jan 1;179(1):27-38
pubmed: 24100956
Diabetologia. 2008 May;51(5):726-35
pubmed: 18292986
Sci Rep. 2019 Jun 13;9(1):7727
pubmed: 31197227
Vaccine. 2014 Sep 22;32(42):5390-8
pubmed: 25108215
BMJ. 2001 Apr 14;322(7291):889-92
pubmed: 11302899
Diabetes Metab Res Rev. 2008 Mar-Apr;24(3):211-22
pubmed: 17968982
JAMA Pediatr. 2019 Mar 1;173(3):280-282
pubmed: 30667473
Virus Res. 2014 Jan 22;179:73-84
pubmed: 24246305
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Future Virol. 2016 Oct;11(10):699-708
pubmed: 27840654
Am J Epidemiol. 2009 Jun 15;169(12):1428-36
pubmed: 19363100
PLoS Pathog. 2014 Mar 27;10(3):e1003998
pubmed: 24676425
JAMA Pediatr. 2013 Sep;167(9):808-15
pubmed: 23836309
Lancet. 2016 Jun 4;387(10035):2340-2348
pubmed: 27302273
Eur J Epidemiol. 2005;20(5):429-34
pubmed: 16080591
Acad Pediatr. 2018 Sep - Oct;18(7):754-762
pubmed: 29604461
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
Curr Opin Immunol. 2005 Dec;17(6):616-23
pubmed: 16216484
MMWR Morb Mortal Wkly Rep. 2019 Feb 08;68(5):112-114
pubmed: 30730870
Diabetes Care. 2012 Dec;35(12):2553-8
pubmed: 23043167
J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):257-260
pubmed: 28992205
Pediatr Infect Dis J. 2017 Jul;36(7):674-675
pubmed: 28399059
Diabetes Care. 1999 Oct;22(10):1698-702
pubmed: 10526738
Epidemiology. 2014 Jul;25(4):576-82
pubmed: 24815306

Auteurs

Jason M Glanz (JM)

Institute for Health Research, Kaiser Permanente Colorado, Aurora.
Department of Epidemiology, Colorado School of Public Health, Aurora.

Christina L Clarke (CL)

Institute for Health Research, Kaiser Permanente Colorado, Aurora.

Stanley Xu (S)

Institute for Health Research, Kaiser Permanente Colorado, Aurora.

Matthew F Daley (MF)

Institute for Health Research, Kaiser Permanente Colorado, Aurora.

Jo Ann Shoup (JA)

Institute for Health Research, Kaiser Permanente Colorado, Aurora.

Emily B Schroeder (EB)

Institute for Health Research, Kaiser Permanente Colorado, Aurora.
Department of Endocrinology, Parkview Health and Parkview Physicians Group, Fort Wayne, Indiana.

Bruno J Lewin (BJ)

Kaiser Permanente Department of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena.

David L McClure (DL)

Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, Wisconsin.

Elyse Kharbanda (E)

Division of Research, HealthPartners Institute, Minneapolis, Minnesota.

Nicola P Klein (NP)

Kaiser Permanente Division of Research, Kaiser Permanente of Northern California, Oakland.

Frank DeStefano (F)

Immunization Safety Office, Vaccine Safety Datalink, Centers for Disease Control and Prevention, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH